In Silico Proof of the Effect of Quercetin and Umbelliferone as Alpha-Amylase Inhibitors, Which Can Be Used in the Treatment of Diabetes
Yazarlar (1)
Prof. Dr. Ergin Murat ALTUNER Kastamonu Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (ESCI dergilerinde yayınlanan tam makale)
Dergi Adı KASTAMONU UNIVERSITY JOURNAL OF FORESTRY FACULTY
Dergi ISSN 1303-2399 Wos Dergi
Dergi Tarandığı Indeksler E-SCI
Makale Dili İngilizce Basım Tarihi 01-2022
Cilt / Sayı / Sayfa 22 / 3 / 202–216 DOI 10.17475/kastorman.1215281
Makale Linki https://dergipark.org.tr/tr/pub/kastorman/issue/74120/1215281
UAK Araştırma Alanları
Biyokimya
Özet
Aim of study The aim of this study is to show the in silico evidences about the potential use of quercetin and umbelliferone as α-amylase inhibitors, which is important for the treatment of diabetes.Material and methods The possible conformations and orientations of quercetin, umbelliferone, and acarbose, in binding to the active sites of alpha-amylase, were analysed by CASTp server. The molecular dockings of these compounds to the potential active site were performed by AutoDock Tools to obtain 3D interactions and binding energies. In addition, the interaction scores were calculated by iGEMDOCK. The 2D enzyme-inhibitor interactions, which clearly show the interactions at the active sites, were analysed by LigPlot+. The drug-likeness properties of quercetin and umbelliferone were compared to acarbose by DruLiTo software and SWISSADME server. The absorption, distribution, metabolism, excretion, and toxicity (ADMET) scores, which present the pharmacokinetic properties of the compounds were analysed by ADMETLab, admetSAR, and PreADMET serversMain results: As a result, the α-amylase inhibitor activity and the potential use of quercetin and umbelliferone were proved in silico.Highlights The results of the study clearly put forward that quercetin and umbelliferone could have possible medicinal use in the treatment of diabetes
Anahtar Kelimeler
Quercetin | Umbelliferone | Acarbose | Alpha-Amylase | Inhibitor | Molecular Docking | ADMET